Harvard Bioscience (HBIO) Other Operating Expenses (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Other Operating Expenses data on file, last reported at $6.2 million in Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $6.2 million, down 88.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.7 million (down 68.23% YoY), and the FY2025 annual result was $71.9 million, up 147.35% from the prior year.
• Other Operating Expenses held at $6.2 million in Q1 2026 per HBIO's latest filing, from $6.2 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $54.3 million in Q1 2025 and troughed at $5.5 million in Q3 2025.
• A 5-year average of $9.8 million and a median of $7.4 million in 2023 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2025 and 2026: Other Operating Expenses soared 561.38% in 2025, then slumped 88.59% in 2026.
• A 5-year view of Other Operating Expenses shows it stood at $7.6 million in 2022, then climbed by 0.69% to $7.6 million in 2023, then dropped by 9.97% to $6.9 million in 2024, then declined by 10.32% to $6.2 million in 2025, then grew by 0.49% to $6.2 million in 2026.
• Business Quant data shows HBIO's Other Operating Expenses at $6.2 million in Q1 2026, $6.2 million in Q4 2025, and $5.5 million in Q3 2025.